AC Immune SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AC Immune SA
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.
Changing payer mix in diabetes due to the impacts of COVID-19 may be a central focus of Lilly's second quarter earnings call.
As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.
- Drug Discovery Tools
- Large Molecule
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
- AC Immune, Ltd.